LENZ Therapeutics (LENZ) Receivables (2025 - 2026)

LENZ Therapeutics (LENZ) posted quarterly Receivables of $343000.0 for Q1 2026, up 4.26% quarter-over-quarter from $329000.0 in Q4 2025.

LENZ Therapeutics (LENZ) Receivables (2025 - 2026) Analysis & Trends

LENZ Therapeutics (LENZ) has reported Receivables for 2 consecutive years, with $343000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Receivables changed N/A year-over-year to $343000.0; the TTM figure through Mar 2026 stood at $343000.0 (changed N/A YoY), while the FY2025 annual figure was $329000.0, changed N/A from the prior year.
Receivables climbed to $343000.0 in Q1 2026 per LENZ's latest filing, from $329000.0 in the prior quarter.
Across five years, Receivables topped out at $343000.0 in Q1 2026 and bottomed at $329000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	138.83 Bn	130.98 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	85.79 Bn	77.79 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.95 Bn	59.77 Bn	1.37 Bn	1.93 Bn
4	Moderna	58.59 Bn	53.46 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.93 Bn	36.83 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	31.52 Bn	28.21 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	27.98 Bn	9.58 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	-
10	LENZ Therapeutics	148.40 Mn	148.40 Mn	5.21 Mn	442,000.00

Download Data